Clinical Trial: Summary: Study of Gamma Knife Radio Surgery and Temozolomide for Patients with
1- 4 Unresected Brain Metastases

http://www.centerwatch.com/patient/studies/stu87321.html

Summary: Study of Gamma Knife Radio Surgery and Temozolomide for
Patients with 1- 4 Unresected Brain Metastases
The purpose of this study is to determine if Gamma Knife radiosurgery
with Temodar improves the overall survival time of patients with one to
four brain metastases (cancer to the brain). All patients will receive
stereotactic radiosurgery (Gamma Knife), done on a single day,
outpatient procedure and chemotherapy with temodar may be given up to
24 months, depending on your tumor response.

Patient Inclusion Criteria

Confirmed diagnosis of cancer with 1-4 brain metastases.
No previous cranial radiation.
No chemotherapy within one month prior to treatment.
No prior surgery for brain metastases.
No allergy to MRI contrast dye.
Age > 18.
Patient Exclusion Criteria

Diagnosis of lymphoma, small cell lung cancer and germ cell tumor.
Systemic therapy within 1 month prior to treatment.
Major medical illnesses or psychiatric impairments, which in the
investigator's opinion will prevent administration of completion of the
protocol therapy and/or interfere with follow-up.
All patients who have undergone a complete resection of all known brain
metastases.

Contact:

Laszlo Mechtler, MD
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY 14263
Telephone: 716-845-3154
Email: Laszlo.mechtler@roswellpark.org 

This site is run by CenterWatch, a publishing company that focuses on
the clinical trials industry. The information provided in this service
is designed to help patients find clinical trials that may be of
interest to them, and to help patients contact the centers conducting
the research. CenterWatch is neither promoting this research nor
involved in conducting any of these trials.

Trial listings updated: February 17, 2006 at 3:52:01 PM